Journal ArticleDOI
N-terminal pro-B-type natriuretic peptide should be used in all dyspneic patients in the ED.
TLDR
Although the patient had the symptoms of bilateral ptosis and diplopia, dysarthria, dysphagia, and respiratory muscle weakness, she did not show any symptoms of injury of the pyramidal tracts, which were most common when bilateral brain stem lesions were involved.Abstract:
lesions in the brain stem. Although the patient had the symptoms of bilateral ptosis and diplopia, dysarthria, dysphagia, and respiratory muscle weakness, she did not show any symptoms of injury of the pyramidal tracts, which were most common when bilateral brain stem lesions were involved. Her motor system symptoms were the injuries of lower motor neuron or peripheral nerve symptoms. Hence, brain stem lesions were not considered. In addition, this patient was ventilated 3 days after admission, and brain magnetic resonance imaging could not be performed.read more
Citations
More filters
Iconographies supplémentaires de l'article : Natriuretic peptide testing in EDs for managing acute dyspnea: a meta-analysis
TL;DR: The current evidence remains inconclusive on whether systematic natriuretic peptide testing is useful for the management of patients presenting to ED with acute dyspnea.
Journal ArticleDOI
Plasma B-type natriuretic peptide in congenital heart disease☆
TL;DR: Although BNP may be used as a diagnostic marker for CHD, except for cardiac diseases, elevated BNP levels may be seen in several diseases, and the time of BNP measurement is an important because infants may be severely influenced above conditions.
References
More filters
Journal ArticleDOI
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure : an international pooled analysis of 1256 patients : the International Collaborative of NT-proBNP Study
James L. Januzzi,Roland R.J. van Kimmenade,John G. Lainchbury,Antoni Bayes-Genis,Jordi Ordóñez-Llanos,Miguel Santalo-Bel,Yigal M. Pinto,Mark Richards +7 more
TL;DR: In this multi-centre, international study, NT-proBNP testing was valuable for diagnostic evaluation and short-term prognosis estimation in dyspnoeic subjects with suspected or confirmed acute HF and should establish broader standards for use of the NT- ProBNP in dysPNoeic patients.
Iconographies supplémentaires de l'article : Natriuretic peptide testing in EDs for managing acute dyspnea: a meta-analysis
TL;DR: The current evidence remains inconclusive on whether systematic natriuretic peptide testing is useful for the management of patients presenting to ED with acute dyspnea.
Journal ArticleDOI
Natriuretic peptide testing in EDs for managing acute dyspnea: a meta-analysis
TL;DR: In this article, the authors performed a systematic review and meta-analysis of randomized controlled trials assessing the usefulness of B-type natriuretic peptide (BNP) or its N-terminal fragment (NT-proBNP), in the management of patients presenting with dyspnea into ED.
Journal ArticleDOI
Predictive cutoff point of admission N-terminal pro-B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure.
Yalcin Golcuk,Burcu Golcuk,Yalçın Velibey,Deniz Oray,Ozge Duman Atilla,Ayfer Colak,Yusuf Kurtulmus,Aydin Yildirim,Mehmet Eren +8 more
TL;DR: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute heart failure at 30 days and 1 year after admission.
Journal ArticleDOI
N-Terminal pro B-type natriuretic peptide testing for short-term prognosis in breathless older adults ☆
Camille Chenevier-Gobeaux,J.-C. Allo,Martine Arthaud,R. Achkar,Yan-Eric Claessens,Ohvanesse G. Ekindjian,Bruno Riou,Patrick Ray +7 more
TL;DR: NT-proBNP higher than 3855 pg/mL or higher at admission is associated with in-hospital mortality in patients aged 75 years and older admitted for dyspnea.